Amivantamab plus Lazertinib in Atypical EGFR-mutated Advanced NSCLC: Results from CHRYSALIS-2

Opinion
Video

Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      4 experts in this video
      The Treatment Landscape For Advanced EGFR-Mutant NSCLC
      4 experts in this video
      Clinical Case: EGFR-Mutant (Exon 19 del) Advanced NSCLC
      Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
      Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-Seeking
      Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
      Elucidating the Safety Profile of Double Lung Transplantation
      Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
      Identifying the Treatment Landscape for Advanced Lung Cancers
      2 experts in this video
      COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best Practices
      2 experts in this video
      Operational Considerations: Workflow Adjustments and Monitoring Systems for Effective COCOON Implementation
      2 experts in this video
      Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
      2 experts in this video
      Measuring Impact: Observed Differences in Dermatologic AEs Between COCOON Protocol and Standard Approaches
      Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
      Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLC
      Related Content
      AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

      The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

      ONCOLOGY Staff
      June 24th 2025
      Article

      AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

      Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting

      Stephen V. Liu, MD;Joshua K. Sabari, MD
      June 23rd 2025
      Podcast

      Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.

      Dato-DXd Earns FDA Accelerated Approval in Pretreated EGFR-Mutated mNSCLC

      Roman Fabbricatore
      June 23rd 2025
      Article

      The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.

      Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      June 16th 2025
      Podcast

      Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.

      FDA Approves Taletrectinib in ROS1+ NSCLC

      Ariana Pelosci
      June 11th 2025
      Article

      Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.

      Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

      Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC

      Roman Fabbricatore
      June 9th 2025
      Article

      Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.